

Amended Claims With Mark-ups to Show Changes Made

- 1 (amended) A pharmaceutical tablet composition comprising an effective amount of amlodipine free base and at least one pharmaceutically acceptable excipient; wherein said amlodipine free base is selected from the group consisting of crystalline Form I amlodipine free base, crystalline Form II amlodipine free base, and mixtures thereof. [said tablet exhibits low punch residue.]
- 8 (amended). The composition according to claim 1, wherein said amlodipine free base is crystalline Form I amlodipine free base. [amorphous amlodipine free base.]
- 40 (amended). The composition according to claim 36, wherein said excipient is anhydrous calcium hydrogen phosphate and said composition [compositions] further comprises microcrystalline cellulose; and wherein said tablet leaves an average residue on the tablet punch of 0.6 $\mu\text{g}/\text{cm}^2$ per tablet or less.

Clean Set of Amended Claims

B1 1 (amended) A pharmaceutical tablet composition comprising an effective amount of amlodipine free base and at least one pharmaceutically acceptable excipient; wherein said amlodipine free base is selected from the group consisting of crystalline Form I amlodipine free base, crystalline Form II amlodipine free base, and mixtures thereof.

B2 8 (amended). The composition according to claim 1, wherein said amlodipine free base is crystalline Form I amlodipine free base.

B3 40 (amended). The composition according to claim 36, wherein said excipient is anhydrous calcium hydrogen phosphate and said composition further comprises microcrystalline cellulose; and wherein said tablet leaves an average residue on the tablet punch of 0.6 $\mu\text{g}/\text{cm}^2$ per tablet or less.

C. Please add new claims 41 and 42 as follows:

B4 41 (New). The composition according to claim 1, wherein said composition is in the form of a round tablet.

42 (New). The composition according to claim 41, wherein said tablet is a round tablet having a diameter of about 20 mm.
